Dianthus Therapeutics announced Q1 2026 financial results and key business updates, including an early go decision in their Phase 3 CAPTIVATE trial for claseprubart in CIDP after achieving 20 responders early. The company is on track to start a Phase 3 trial for generalized Myasthenia Gravis mid-2026 and expects top-line results by late 2028. They also continue Phase 2 trials for Multifocal Motor Neuropathy and Phase 1 trials for DNTH212 targeting rheumatology diseases. Dianthus strengthened its cash position to approximately $1.2 billion after raising $719 million in a public offering, providing runway into 2030. These developments position Dianthus to advance its pipeline of next-generation autoimmune therapies.
STARLUX Airlines has introduced the AIRSORAYAMA Silver, the world's largest flying canvas, featuring a unique liquid-metal livery designed by Japanese artist Hajime Sorayama. The aircraft, an Airbus A350-1000, was unveiled in Toulouse and will be pil...
Stellar network validators will vote on July 8 to approve Protocol 27, known as Zipper, which introduces native authentication delegation and improves security by fixing replay vulnerabilities in Soroban smart contracts. This upgrade simplifies accou...
About $410 million in leveraged crypto positions were liquidated within 24 hours, driven mainly by Bitcoin and Ethereum losses. Long positions accounted for nearly 63% of liquidations, indicating traders betting on price rises were hit hardest. Howev...
The DeXe (DEXE) token has surged 17.5% in the last 24 hours, driven by a 201% increase in daily trading volume, signaling strong market confidence. Unlike other AI sector tokens, DeXe shows notable bullish momentum, supported by steady capital inflow...
Netflix is seeing more viewers abandon shows before the second season, driven by frequent cancellations, long waits between seasons, and content tailored more for algorithms than storytelling. The streaming giant's binge model, once revolutionary aga...
